

Cemiplimab for treating advanced cutaneous squamous cell carcinoma

Information for the public

Published: 29 June 2022

www.nice.org.uk

Cemiplimab (Libtayo) is available on the NHS as a possible treatment for metastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not suitable. It is only recommended if it is stopped at 24 months, or earlier if your disease progresses.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [British Association of Skin Cancer Specialist Nurses](#)
- [British Skin Foundation](#), 020 7391 6341
- [Melanoma UK](#), 0808 171 2455
- [Skcin: The Karen Clifford Skin Cancer Charity](#), 0115 981 9116
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4663-1